+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 64Years
All Genders
ID07616128

Randomized, Double-Blind Study of Daily EVO756 Doses Versus Placebo for Migraine Prevention in Adults

Led by Evommune, Inc. · Updated on 2026-11-04

330

Participants Needed

45

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating EVO756, a medication taken orally, to study its effects on adults with migraine. This phase 2 trial aims to test the efficacy and safety of two different daily doses of EVO756 compared to a placebo. The study focuses on preventing migraines and is sponsored by Evommune, Inc. Participants will be randomly assigned to one of three groups one receiving daily Dose 1 of EVO756, another receiving daily Dose 2 of EVO756, or a placebo group taking a daily placebo pill. The treatment period lasts 12 weeks, during which participants take their assigned medication every day. Throughout the study, participants will have regular assessments to track changes in the number of monthly migraine and headache days, medication use, and any side effects. The main measurement is the change in monthly migraine days during the last month of treatment. Safety monitoring continues through week 16. The overall study runs from July 2026 to November 2027, with participants involved for at least 12 weeks of treatment and follow-up.

CONDITIONS

Brief Title

Study of EVO756 in Adults With Migraine

Research Team

N

Nichole Baio

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here